Form 4: Cabaletta Bio Director Receives Stock Option Grant

Director Scott C. Brun was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Summary

• Director Scott C. Brun acquired 22,000 stock options in Cabaletta Bio, Inc. (CABA).
• The options have an exercise price of $3.22 per share.
• The grant date for these options is June 9, 2026.
• The options are set to expire on June 8, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock.
• The exercise price of $3.22 may be subject to market fluctuations relative to the future trading price of CABA.

Future Outlook

The options vest in full on the earlier of June 9, 2027, or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The use of time-based vesting (one year) is consistent with standard equity compensation practices for non-employee directors in small-cap biotech firms.

Stakeholder Impact

• Minor dilution impact for existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 9, 2027, or the next annual meeting date.

Key Dates

Keywords

Cabaletta Bio, CABA, Form 4, Insider Trading, Stock Options, Director Compensation